Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 9, 2016
GAITHERSBURG, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its second quarter 2016 financial and operating results after the close of U.S. financial markets on Tuesday, August 9, 2016.
Management will host a conference call to discuss the quarterly financial results and provide an update on corporate activities.
Conference call details are as follows:
| Date: | Tuesday, August 9, 2016 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 59901631 | |
| Via web: | www.novavax.com, “Investors”/ “Events” | |
Conference call replay:
| Date: | Starting at 7:30 p.m. ET, August 9, 2016 until August 16, 2016 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 59901631 | |
| Via web: | www.novavax.com, “Investors”/ “Events” | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations ir@novavax.com 240-268-2000
© Copyright Globe Newswire. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire.
